Last reviewed · How we verify

Doravirine, Tenofovir, Lamivudine - Blinded

Merck Sharp & Dohme LLC · Phase 2 active Small molecule

Doravirine, Tenofovir, Lamivudine - Blinded is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 2 development. Also known as: MK-1439A.

At a glance

Generic nameDoravirine, Tenofovir, Lamivudine - Blinded
Also known asMK-1439A
SponsorMerck Sharp & Dohme LLC
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Doravirine, Tenofovir, Lamivudine - Blinded

What is Doravirine, Tenofovir, Lamivudine - Blinded?

Doravirine, Tenofovir, Lamivudine - Blinded is a Small molecule drug developed by Merck Sharp & Dohme LLC.

Who makes Doravirine, Tenofovir, Lamivudine - Blinded?

Doravirine, Tenofovir, Lamivudine - Blinded is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

Is Doravirine, Tenofovir, Lamivudine - Blinded also known as anything else?

Doravirine, Tenofovir, Lamivudine - Blinded is also known as MK-1439A.

What development phase is Doravirine, Tenofovir, Lamivudine - Blinded in?

Doravirine, Tenofovir, Lamivudine - Blinded is in Phase 2.

Related